Bulletin
Investor Alert

Lipocine Inc.

NAS: LPCN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Lipocine Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 28, 2023, 6:13 p.m.

LPCN
/zigman2/quotes/202742746/composite

$

0.33

Change

+0.0020 +0.61%

Volume

Volume 357

Quotes are delayed by 20 min

/zigman2/quotes/202742746/composite

Today's close

$ 0.32

$ 0.33

Change

+0.01 +3.63%

Day low

Day high

$0.31

$0.33

Open

52 week low

52 week high

$0.27

$1.64

Open

Company Description

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabo...

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Valuation

Price to Sales Ratio

70.38

Price to Book Ratio

0.99

Enterprise Value to EBITDA

0.42

Enterprise Value to Sales

-10.18

Efficiency

Revenue/Employee

29,412.00

Income Per Employee

-632,861.00

Receivables Turnover

1.10

Total Asset Turnover

0.01

Liquidity

Current Ratio

20.34

Quick Ratio

20.34

Cash Ratio

19.38

Profitability

Gross Margin

98.11

Operating Margin

-2,423.88

Pretax Margin

-2,151.59

Net Margin

-2,151.73

Return on Assets

-23.90

Return on Equity

-26.50

Return on Total Capital

-29.02

Return on Invested Capital

-26.50

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Spyridon Papapetropoulos 49 2022 Independent Director
Dr. Mahesh V. Patel 62 1997 President, Chief Executive Officer & Director
Dr. George G Nomikos - 2022 Chief Medical Officer
Dr. Anthony DelConte 61 - Chief Medical Director
Dr. Nachiappan Chidambaram - 2014 Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/22/2022 Spyridon Papapetropoulos
Director 		21,739   Acquisition at $0.47 per share. 10,217
11/14/2022 Mahesh V. Patel
CEO and President; Director 		75,000   Acquisition at $0.39 per share. 29,250
09/27/2022 Mahesh V. Patel
CEO and President; Director 		100,000   Acquisition at $0.41 per share. 41,000
05/17/2022 Krista Fogarty
Principal Accounting Officer 		12,500   Acquisition at $0.86 per share. 10,750
05/16/2022 Mahesh V. Patel
CEO and President; Director 		50,000   Acquisition at $0.77 per share. 38,500
11/18/2021 Mahesh V. Patel
CEO and President; Director 		25,000   Acquisition at $1.09 per share. 27,250
12/31/2020 John W. Higuchi
Director 		5,000   Disposition at $1.35 per share. 6,750
12/31/2020 John W. Higuchi
Director 		1,700   Disposition at $1.34 per share. 2,278
12/16/2020 Mahesh V. Patel
CEO and President; Director 		15,000   Disposition at $1.35 per share. 20,250
12/16/2020 Morgan R. Brown
EVP and CFO 		8,437   Disposition at $1.35 per share. 11,389
12/16/2020 Mahesh V. Patel
CEO and President; Director 		45,000   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 John W. Higuchi
Director 		3,750   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Morgan R. Brown
EVP and CFO 		28,125   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Stephen Anthony Hill
Director 		7,500   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Richard Dana Ono
Director 		5,250   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Jeffrey Arvin Fink
Director 		5,625   Derivative/Non-derivative trans. at $0 per share. 0
12/05/2020 Mahesh V. Patel
CEO and President; Director 		122,978   Derivative/Non-derivative trans. at $0 per share. 0
12/05/2020 Morgan R. Brown
EVP and CFO 		70,754   Derivative/Non-derivative trans. at $0 per share. 0
12/04/2020 Mahesh V. Patel
CEO and President; Director 		43,500   Disposition at $1.57 per share. 68,295
12/04/2020 Morgan R. Brown
EVP and CFO 		17,250   Disposition at $1.57 per share. 27,082
12/04/2020 Mahesh V. Patel
CEO and President; Director 		145,000   Derivative/Non-derivative trans. at $0 per share. 0
12/04/2020 Morgan R. Brown
EVP and CFO 		57,500   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/lpcn

MarketWatch News on LPCN

  1. Lipocine stock price target cut to $2.50 from $4.00 at Ladenburg Thalmann

    9:19 a.m. Nov. 10, 2022

    - Tomi Kilgore

  6. Lipocine shares plummet 35% after FDA fails to approve its testosterone replacement therapy

    7:03 a.m. May 9, 2018

    - Emma Court

  7. Lipocine downgraded to hold from buy at Canaccord

    11:22 a.m. Jan. 11, 2018

    - Tomi Kilgore

  8. Lipocine stock price target cut to $2 from $11 at Canaccord

    11:23 a.m. Jan. 11, 2018

    - Tomi Kilgore

  9. 6 stocks to watch

    3:38 p.m. Sept. 9, 2015

    - The Trading Deck

  10. 4 stocks to watch

    3:21 p.m. Sept. 2, 2015

    - The Trading Deck

  11. Bed Bath & Beyond surges on earnings

    5:39 p.m. Sept. 23, 2014

    - MarketWatch

/news/nonmarketwatch/company/us/lpcn

Other News on LPCN

  1. 10-K: LIPOCINE INC.

    9:34 a.m. March 10, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: LIPOCINE INC.

    9:04 a.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. 10-Q: LIPOCINE INC.

    8:06 a.m. May 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. MVIS, MRIN and CLVR among mid-day movers

    12:46 p.m. March 29, 2022

    - Seeking Alpha

  13. BGVF, VYNT and SNMP among pre market gainers

    8:38 a.m. Nov. 4, 2021

    - Seeking Alpha

  15. Warning: LPCN is at high risk of performing badly

    4:54 a.m. Oct. 27, 2021

    - Seeking Alpha

  16. AG, FRO and WATT among pre market gainers

    8:33 a.m. Oct. 19, 2021

    - Seeking Alpha

  18. FDA affirms class 1 NDA resubmission for Lipocine's Tlando

    8:35 a.m. Sept. 28, 2021

    - Seeking Alpha

  19. Lipocine discloses mid-stage data for NASH candidate

    8:29 a.m. Aug. 25, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Lipocine, Inc.

675 Arapeen Drive

Suite 202

Salt Lake City, Utah 84108

Phone

1 8019947383

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$500,000

Net Income

$-10.76M

Employees

17.00

Annual Report for LPCN

/news/pressrelease/company/us/lpcn

Press Releases on LPCN

  1. Are These Pennies Heads Up? (EPAZ, LPCN, XALL, ARDS)

    5:00 a.m. March 14, 2023

    - TheNewswire.ca

  2. Are These Pennies Heads Up? (EPAZ, LPCN, XALL, ARDS)

    5:00 a.m. March 14, 2023

    - News Direct

  5. Lipocine to Present at Biotech Showcase

    9:00 a.m. Jan. 5, 2023

    - PR Newswire - PRF

  12. Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

    4:10 p.m. Sept. 22, 2022

    - PR Newswire - PRF

  15. FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

    8:00 a.m. July 11, 2022

    - PR Newswire - PRF

  16. LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

    8:00 a.m. June 14, 2022

    - PR Newswire - PRF

  21. Loading more headlines...
Link to MarketWatch's Slice.